UNASSIGNED: This study was designed to investigate the prognostic impact of elevated platelet to lymphocyte ratio (PLR) on survival for @entity420 ( @entity420 ) treated with neoadjuvant chemotherapy in a curative intent. From 2004 to 2014, 153 consecutive @entity1 with @entity420 were included. PLR was measured at first diagnosis. Receiver Operating Characteristic curve analysis was performed to determinate PLR threshold. Cox multivariate model was used to assess correlation between PLR and survival. Cut-off value for PLR was 192, which identified 2 groups of @entity1 : low (n  =  122) and high PLR value (n  =  31). Both groups were comparable by @entity1 (age, sex, ASA score) and @entity5 characteristics (differentiation, @entity2802 stage, location). Five year @entity1349 ( @entity1349 ) was 65%. @entity1349 and DFS were reduced in the high PLR group: p  =  0.019 and p  =  0.016, respectively. PLR was associated with increased recurrence (54.8% vs. 35.2%, p  =  0.046) and @entity5 (41.9% vs. 23.8%, p  =  0.043) rates. On multivariate analysis, elevated PLR was associated with decreased DFS (HR  =  2.85, 95%CI  =  1.54-5.26, p  =  0.001) and @entity1349 (HR  =  2.47, 95%CI  =  1.21-5.01, p  =  0.012). This study demonstrates that elevated PLR is associated with poor @entity1349 and DFS for @entity420 treated with a curative intent and has the potential to be a useful prognostic biomarker for treatment planning.

Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-related death', 'tumour'] @entity2802 :: ('10178', 'Gene') :: ['TNM'] @entity420 :: ('MESH:D000230', 'Disease') :: ['oesophageal and junctional adenocarcinoma', 'OJA'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1 :: (9606,Species) :: ['patients']
